Type XVII collagen ELISA indices significantly decreased after bullous pemphigoid remission

Kusajima, Erika; Akiyama, Masashi; Sato, Megumi; Natsuga, Ken; Shimizu, Hiroshi

doi:10.1111/j.1365-4632.2010.04324.x

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, our study showed that lower anti-BP180 IgG titres at Week 12 were associated with a higher likelihood of achieving subsequent clinical remission. This is consistent with other studies which found that antibody titres signifi cantly decreased after remission, 5,8,12,13 or during treatment toward disease control. [9][10][11] However, an interesting fi nding was that 68% of patients had persistent elevated antibody titres despite achieving clinical remission and that the antibody titres in these patients were not predictive of subsequent disease fl are.…”

Section: Discussionsupporting

confidence: 93%

Anti-BP180 NC16A IgG Titres as an Indicator of Disease Activity and Outcome in Asian Patients with Bullous Pemphigoid

Cai

Lim

et al. 2015

Ann Acad Med Singap

View full text Add to dashboard Cite

Introduction: Anti-BP180 IgG titres were observed to parallel disease activity in case series of bullous pemphigoid (BP). This study aimed to examine whether anti-BP180 titres are an indicator of disease severity, clinical course and outcome in Asian patients with BP. Materials and Methods: This was a prospective observational study conducted between March 2005 and March 2008 in the Immunodermatology Clinic at the National Skin Centre, Singapore. Disease activity and anti-BP180 IgG titres were measured 4-weekly for 12 weeks and during disease fl ares and clinical remission. Associations between anti-BP180 titres and disease activity, disease fl are, clinical remission and cumulative prednisolone dose were examined. Results: Thirty-four patients with newly diagnosed BP were recruited. Median follow-up duration was 3 years. Notable correlations between disease activity and anti-BP180 titres were at baseline (r = 0.51, P = 0.002), and disease fl are (r = 0.85, P <0.001). Lower titres at Week 12 were associated with greater likelihood of clinical remission (P = 0.036). Post hoc, patients with anti-BP180 titres above 87.5 U/mL at time of diagnosis who reached remission within 2 years of diagnosis received signifi cantly higher cumulative doses (mg/kg) of prednisolone (median, 72.8; range, 56.5 to 127.1) than those with titres <87.5 U/mL (median, 44.6; range, 32.5 to 80.8); P = 0.025). Conclusion: Anti-BP180 titres may be a useful indicator of disease activity at time of diagnosis and at disease fl are. Lower titres at Week 12 may predict greater likelihood of clinical remission. Titres above 87.5 U/mL at time of diagnosis may suggest the need for higher cumulative doses of prednisolone to achieve remission within 2 years. Key words: Immunobullous disease, Subepidermal skin blistering, Tense skin blisters

show abstract

Section: Discussionsupporting

confidence: 93%

Anti-BP180 NC16A IgG Titres as an Indicator of Disease Activity and Outcome in Asian Patients with Bullous Pemphigoid

Cai

Lim

et al. 2015

Ann Acad Med Singap

View full text Add to dashboard Cite

show abstract

“…Moreover, the BPAG2 ELISA values were reported to be more closely correlated with initial extent of BP lesions than were the BPAG1 ELISA values. [26] Kusajima et al [27] demonstrated that the BP180-NC16A ELISA indices correlated with BP disease remission more accurately than IIF titers, and represented a useful tool to not only detect BP disease remission but also to assess the efficacy of BP treatment. Tampoia et al [28] reported that the diagnostic specificity for both tests together was over 98%, and diagnostic sensitivity was 90% and 60% for anti-BP180 and anti-BP230, respectively.…”

Section: Discussionmentioning

confidence: 99%